Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL

NCT07538180 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Newly Diagnosed MYC/BCL2 Double-expressor DLBCL

Interventions

DRUG: SCR Regimen Sequential with R-CHOP and Maintenance Therapy

Sponsor

Sun Yat-sen University